ANG Lifesciences Share Price Today | Stock Price & ANG Lifesciences Share Screener
As of November 19, 2026, the live ANG Lifesciences share price (BSE: ANG) is ₹37.49, down 1.03% from the previous close, with shares trading between ₹37.21 and ₹41.78 in today's trading session, and a 52-week range of ₹18.42–₹42.83. Track ANG Lifesciences market cap to gauge the company's total market size. Use the ANG Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today ANG Lifesciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹20 and net income of ₹-2, an operating margin of -1.0% and a profit margin of -10.0%.
ANG Lifesciences Share Price Chart
Track the current stock price of ANG Lifesciences with an interactive chart. Analyse ANG share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete ANG Lifesciences stock quote in one place.
The quote of ₹37.49 sits between the 52-week low of ₹18.42 and the 52-week high of ₹42.83, and the latest session moved -1.03% from the previous close.
ANG Lifesciences Company Profile - Fundamental Screener
Screen ANG Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ANG shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE236W01016.
Company Details
Classification
Identifiers and Leadership
ANG Lifesciences Balance Sheet Screener
Screen ANG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹209, down from ₹230 in 2025.
Latest statistics put total assets at ₹209 and shareholder funds at ₹53, with a leverage ratio of 1.39.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
Assets |
|||||
| Total Assets | 209 | 230 | 242 | 278 | 291 |
| Current Assets | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 51 | 57 | 58 | 88 | 93 |
Liabilities |
|||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7 | 22 | 22 | 29 | 41 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||
| Total Equity | 53 | 64 | 76 | 86 | 84 |
| Share Capital | 13 | 13 | 13 | 13 | 10 |
| Reserves & Surplus | 35 | 46 | 59 | 69 | 69 |
ANG Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen ANG Lifesciences income statement and profit fundamentals. Analyze ANG quarterly results. ANG Lifesciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹20 and net profit was ₹-2, equal to earnings per unit of ₹-1.59, at an operating margin of -1%.
In that period expenses were ₹20, interest cost ₹2 and tax ₹-2. The next period listed, 2026-Jun, shows revenue of ₹15 and net profit of ₹-4.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 20 | 15 | 24 | 19 | 26 | 25 | 18 | 25 | 33 | 20 | 38 | 49 | 57 | 34 | 19 |
| Expenses | 20 | 17 | 21 | 21 | 26 | 24 | 18 | 27 | 31 | 20 | 36 | 50 | 50 | 32 | 21 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 0 | -2 | 3 | -3 | 0 | 1 | 0 | -2 | 3 | 0 | 2 | -1 | 7 | 2 | -2 |
| Operating Profit % | -1.00% | -13.00% | 11.00% | -14.00% | 0.00% | 3.00% | -4.00% | -9.00% | 7.00% | -9.00% | 4.00% | -26.00% | 12.00% | 5.00% | -10.00% |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 3 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | -4 | -6 | -1 | -6 | -3 | -3 | -4 | -6 | -1 | -4 | -4 | -6 | 2 | -3 | -6 |
| Tax | -2 | -1 | 0 | -1 | 0 | -1 | -2 | -1 | 1 | -1 | 0 | -1 | 1 | 0 | 0 |
| Net Profit | -2 | -4 | -1 | -5 | -3 | -2 | -2 | -5 | -2 | -3 | -4 | -5 | 2 | -2 | -6 |
| EPS | -1.59 | -3.24 | -1.07 | -3.60 | -2.24 | -1.52 | -1.56 | -3.98 | -1.53 | -2.35 | -2.75 | -3.63 | 1.41 | -1.74 | -4.52 |
ANG Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen ANG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹11.
Over the same period, investing activities provided ₹1 and financing activities used ₹12.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|---|
Cash from Operations and Investing | |||||
| Operating Activities | 11 | 0 | -10 | 26 | 25 |
| Investing Activities | 1 | -2 | 20 | -9 | -44 |
Financing and Net Cash | |||||
| Financing Activities | -12 | 2 | -10 | -17 | 20 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 |
ANG Lifesciences Shareholding Pattern Screener
See ANG Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check ANG Lifesciences promoter holding and ownership changes for ANG on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 70.60%, foreign institutions 0.00%, domestic institutions 0.00% and the public 26.42%, spread across 5,666 shareholders.
The shareholder count was 5,666 in 2026-Sept, compared with 5,946 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 26.42% | 26.30% | 26.21% | 26.26% | 26.18% | 26.11% | 26.11% | 25.92% |
| Other Holding | 2.98% | 3.10% | 3.19% | 3.13% | 3.21% | 3.29% | 3.29% | 3.48% |
| Shareholder Count | 5,666 | 5,946 | 5,952 | 6,084 | 6,273 | 6,400 | 6,508 | 6,517 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by ANG Lifesciences. ANG Lifesciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹1.00 | 1.33% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
ANG Lifesciences Stock Index Membership - Nifty & Sensex
See which indices include ANG Lifesciences stock. Check ANG index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
ANG Lifesciences Market Events Screener - Corporate Actions
Get ANG Lifesciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check ANG Lifesciences stock events that may affect ANG share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.
It is followed by Annual General Meeting dated September 30, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-14 | 2026-11-14 | Quarterly Result Announcement | NA | 15.16% |
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | 18.07% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | -2.33% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -5.73% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | 3.50% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -2.04% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -1.68% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -3.93% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -5.27% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -5.83% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.04% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -8.62% |
| 2022-07-13 | 2022-07-14 | Bonus | 1:4 | 36.04% |
| 2021-11-02 | 2021-11-04 | Dividend | ₹ 1.00 /share | 47.69% |
| 2021-09-22 | Bonus | 1:1 | - |
ANG Lifesciences Competitors Screener - Peer Stocks Comparison
Screen ANG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,707 | 40.80 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 295,666 | 87.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 176,844 | 85.00 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 126,547 | 89.90 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 120,159 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,829 | 41.80 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,260 | 39.50 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,321 | 47.90 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,263 | 25.80 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 89,263 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
ANG Lifesciences Company Announcements - News & Reports Screener
Screen ANG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 19, 2026.
The next most recent announcements are dated November 19, 2026 and November 19, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-19 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-11-19 | Financial Results For The Quarter And Half Year Ended 30.09.2026. | - |
| 2026-11-19 | Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2026 | - |
| 2026-11-11 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-10-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-23 | Closure of Trading Window | - |
| 2026-09-07 | Reg. 34 (1) Annual Report. | - |
| 2026-09-07 | Notice Of 20Th AGM Of The Company On Wednesday 30Th September 2026 At 12 :00 Noon. (IST) Through Video Conferencing (VC) / Other Audio Visual Means (OA VM). | - |
| 2026-09-07 | Intimation Of Book Closure | - |
| 2026-09-07 | Intimation Of 20Th Annual General Meeting | - |
| 2026-09-07 | Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For Intimation Of AGM | - |
| 2026-08-14 | Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations 2015 | - |
| 2026-08-14 | Board Meeting Outcome for Board Meeting Outcome For Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations 2015 | - |
| 2026-08-07 | Board Meeting Intimation for Consideration And Approval Of Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2026. | - |
| 2026-07-21 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-19 | Closure of Trading Window | - |
| 2026-06-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹37.49, within a 52-week range of ₹18.42 to ₹42.83. The P/E ratio is -4.00 and the P/B ratio is 1.06, with earnings per unit of ₹-8.43. Market capitalisation stands at ₹50.89 Cr and the dividend yield is 2.65%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on November 21, 2026. This page covers 5 balance sheet periods, 15 income statement periods, 5 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.